Inspire Secures AMA Approval For New Hypoglossal Nerve Stimulation Codes
Inspire Medical Systems (INSP) received AMA approval for new CPT codes covering hypoglossal nerve stimulation procedures, including its Inspire V system. The codes, effective January 1, 2028, aim to simplify reimbursement and expand patient access. CMS will determine reimbursement values, with proposed valuations expected in July 2027. INSP stock closed at $70.78, up 2.05%.
How this was made
The 30-second read
Why it matters
The approval removes a billing barrier, likely improving insurer coverage and patient access, which can translate into higher sales and stock appreciation.
Market read
Regulatory approval of CPT codes is a material catalyst for Inspire Medical, potentially driving share price higher as reimbursement improves.
What to watch
Potential competition from alternative OSA therapies and payer pushback on pricing.
Background
Inspire Medical Systems announced AMA CPT editorial panel approval of new Category I codes for its hypoglossal nerve stimulation system, effective Jan 1 2028.
Ticker impact
AMA CPT code approval for Inspire V hypoglossal nerve stimulation could improve reimbursement and boost adoption.
upward pressure as investors price in better reimbursement prospects
New CPT codes reduce billing uncertainty and may expand market access, a catalyst for revenue growth.
Market effects
May benefit other sleep‑apnea device makers and broader medical‑device reimbursement landscape.
U.S. healthcare reimbursement environment; limited direct regional effect.
Limited to companies with similar CPT‑code dependencies.
Counterpoint
Reimbursement timelines could be slow; CMS valuation may be modest, limiting near‑term upside.
Key entities
- companyInspire Medical Systems, Inc.
Developer of hypoglossal nerve stimulation therapy for obstructive sleep apnea.
- organizationAmerican Medical Association (AMA)
CPT Editorial Panel that approved the new procedural codes.
